- Salix's NDA for crofelemer in HIV-associated diarrhea assigned priority review status
- Genentech's BLA for pertuzumab receives priority review status in previously untreated HER2-positive metastatic breast cancer indication
- FDA reviewers questions efficacy of NeurogesX's Qutenza pain patch in proposed new use
- Shire's Vyvanse approved for maintenance treatment in adults with ADHD
- FDA accepts Ziopharm's IND application for oral formulation of Zymafos
- Private FFS MA plans may be linked with higher costs for beneficiaries, GAO report shows
- Pediatric subspecialty telephone consultations may be cost-saving for Medicaid, research reveals
- Use of mental health services greater in health plans with parity in cost sharing, data find
- Public opinions appear split on health care affordability, satisfaction, survey finds
- In Brief: California Supreme Court
Home :: Nephrology :: Nephrology Conferences
American Society of Nephrology 2008 Renal Week
November 4 - 9, 2008 Philadelphia, PA- Kidney stones increase risk of chronic kidney disease, may increase risk of end-stage renal disease in general population, researchers report
- Kidney transplantation may improve cognitive function among patients with ESRD
- Less-frequent dosing of epoetin alfa efficacious in treating anemia in patients with CKD, new data reveal
- Coronary artery bypass surgery may provide improved long-term survival among patients with end-stage renal disease requiring revascularization procedure
- Low potassium level associated with high blood pressure, despite salt intake, CV risk factors
- FDA committee votes in favor of approving Pfizer's Inlyta for advanced RCC
- FDA staff reviewers say Affymax's peginesatide works as well as available anemia products, needs more safety testing
- FDA reviewers question effectiveness of Pfizer's kidney cancer drug candidate
- Isotechnika, Vifor Pharma sign license agreement for development, commercialization of voclosporin
- Takeda decides not to market peginesatide in Japan
- Pfizer, SFJ Pharma to develop axitinib as adjuvant therapy for renal cancer in Asia
- FDA reviewers question effectiveness of Pfizer's kidney cancer drug candidate
- FDA approves label update for Merck's Vytorin to include efficacy data from SHARP trial, does not approve indication for Vytorin, Zetia to help prevent vascular events in patients with CKD
- Moving to lower-poverty neighborhood associated with potentially important reductions in risk of obesity, diabetes, findings show
- Takeda decides not to market peginesatide in Japan
